Eyes treated with Yutiq experienced lower recurrence rates of noninfectious uveitis than sham-treated eyes in a 36-month phase 3 trial, EyePoint Pharmaceuticals announced in a press release.
The second double-masked, randomized, phase 3 trial enrolled 153 patients in India, with 101 eyes receiving Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) and 52 eyes receiving sham injections.
Eyes treated with Yutiq experienced lower recurrence rates of noninfectious uveitis than sham-treated eyes in a 36-month phase 3 trial.
The recurrence rate of those treated with Yutiq was 46.5% compared with 75% for those treated with sham (P = .001). In addition, 8.9% of Yutiq-treated eyes needed the assistance of adjunctive intraocular/periocular injection medication for uveitic inflammation compared with 51.9% of those treated with sham, the release said. Macular edema was resolved in 75.8% of those treated with Yutiq and 53.8% of those treated with sham.
“We continue to believe Yutiq is a differentiated treatment option compared to existing therapies because of its highly efficacious and solid safety profile, coupled with its convenient, single administration and long-term consistent dosing of drug,” Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, said in the release. “The 36-month results provide additional support in its long-acting potential, a characteristic consistently regarded by treating physicians as a critical treatment advantage. Our commercial efforts are yielding increased reception and adoption from uveitis specialists across the U.S., as well as positive patient feedback on the Yutiq product profile.”